Background

Katie is a Research Officer under the Viral Hepatitis Elimination Program, working on improving treatment access for hepatitis C. Her interests are health equity & economics, infectious disease epidemiology and health policy. Her research approach is interdisciplinary, using a combination of mathematical modelling and empirical work.

Katie is a consultant for the World Health Organization, developing tools and policy for national strategic planning in maternal and child health. Katie also works on health economics in relation to HIV, hepatitis C and tuberculosis treatment, and on vector-borne disease control.

Positions

• 2020 - ongoing - Research Officer, Burnet Institute, Melbourne, Australia
• 2018 - ongoing - Consultant, World Health Organization, Department of Reproductive Health & Research, Geneva, Switzerland
• 2018 - 2018 - Environmental Scientist, Instituto Nacional de Pesquisas Espaciais (INPE), São José dos Campos, Brazil
• 2016 - Scientific Enterprise Consultant, The Nasio Trust, Musanda, Western, Kenya
• 2014 - 2015 - Research Officer, International Prevention Research Institute (IPRI), Lyon, France
• 2012 - Research Assistant, University of Strathclyde, Department of Mathematics and Statistics, Glasgow, UK

Qualifications

• 2019 - PhD Zoology, University of Oxford
• 2014 - MSc Epidemiology, Imperial College London
• 2013 - BA Philosophy, University of Cambridge

Projects (1)

Current (1)

• 

  The Optimise Study: Optimising Isolation, Quarantine and Distancing for COVID-19

Publications (7)

2020 (2)

• Nutritional availability and larval density dependence in Aedes aegypti
  Katherine Heath, Robert S. Paton, Anthony J. Wilson, Michael B. Bonsall
  Ecol Entomol. 2020 Jun; Epub ahead of print
• Minimum costs to manufacture new treatments for COVID-19.
  Hill A, Wang J, Levi J, Heath K, Fortunak J
  J Virus Erad. 2020 Apr; 6(2):61-69

2019 (1)

• Most new HIV infections, vertical transmissions and AIDS-related deaths occur in lower-prevalence countries.
  Joe Kempton, Andrew Hill, Jacob A Levi, Katherine Heath, Anton Pozniak
  J Virus Erad. 2019 Apr; 5(2):92-101

2018 (2)

• Cost-effectiveness analysis of treatment timing considering the future entry of lower-cost generics for hepatitis C.
  Katherine Heath
  Clinicoecon Outcomes Res. 2018 Sep; 10:539-550
• The impact of HIV prevalence, conflict, corruption, and GDP/capita on treatment cascades: data from 137 countries.
  Jacob Levi, Anton Pozniak, Katherine Heath, Andrew Hill
  J Virus Erad. 2018 Apr; 4(2):80-90

2015 (2)

• Higher risks of mother-to-child HIV transmission in countries with lower HIV prevalence: UNAIDS 2013 results for 32 countries with generalised epidemics.
  Andrew Hill, Thomas Dauncey, Jake Levi, Katherine Heath, Carmen Perez Casas
  J Virus Erad. 2015 Oct; 1(4):257-263
• Long-Term Treatment Outcomes of Patients Infected With Hepatitis C Virus: A Systematic Review and Meta-analysis of the Survival Benefit of Achieving a Sustained Virological Response.
  Bryony Simmons, Jawaad Saleem, Katherine Heath, Graham S Cooke, Andrew Hill
  Clin Infect Dis. 2015 Sep; 61(5):730-740

News Articles (1)

2020 (1)

• Drug pricing a barrier to HIV elimination